JNJakub Nowak

Jakub Nowak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jakub Nowak has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modular Surface Engineering of Feline Parvovirus Virus-Like Particles for Antigen Presentation and Receptor-Mediated Cell Targeting

    by Antonina Naskalska, Artur Biela, Jan Rozycki, Kinga Fic, Edyta Kus, Jakub Nowak

    Virus-like particles (VLPs) are non-infectious, multiprotein nanostructures that mimic the architecture of viruses while lacking genetic material. Their structural versatility and safety profile make them promising platforms for biomedical applications, including vaccine development, targeted drug delivery, and diagnostics. Among various functionalization strategies, click-chemistry has emerged as a precise and efficient method for attaching bioactive molecules to VLP surfaces. In this study, we report the production and functionalization of VLPs derived from the feline panleukopenia virus (FPV), a parvovirus closely related to the well-characterized canine parvovirus (CPV). We demonstrate successful expression, assembly, and purification of FPV VLPs, followed by their modification with fluorophores, peptides, oligonucleotides, and proteins using copper-free click-chemistry. Furthermore, using cryo-EM, we structurally characterize FPV VLP functionalized with antigenic peptides, providing detailed insights for further development of such vaccine prototype. Finally, we demonstrate that our FPV VLP specifically transduce feline and human cells expressing transferrin receptor type 1 (TfR), thus validating their potential as a unique platform for future nanotechnological and therapeutic applications.

  • Open Access

    Cryo-EM structure of the Danio rerio tRNA ligase complex

    by Chamera S, Zajko W, Czarnocki-Cieciura M, Jaciuk M, Koziej Ł, Nowak J, Wycisk K, Sroka M, Chramiec-Głąbik A, Śmietański M, et al.

    EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.

  • Clozapine's Molecular Signature: Selective 5‐ HT2A Receptor Downregulation and Signalling in Rat Brain Cortical Regions

    by Sylwia Kedracka‐Krok, Jakub Nowak, Ewelina Fic, Joanna Solich, Piotr Rybczynski, Weronika Romanska, Patrycja Sarga, Katarzyna Pustelny, Marta Dziedzicka‐Wasylewska

    The superior clinical efficacy of clozapine (CLO) in treatment‐resistant schizophrenia remains incompletely understood. To elucidate these mechanisms, we employed a multi‐platform proteomic strategy—combining data‐dependent acquisition (DDA) with fractionation, data‐independent acquisition (DIA) and targeted parallel reaction monitoring (PRM)—to analyse chronic drug‐induced proteomic changes in the prefrontal cortex (PFC) and remaining cerebral cortex (CX) of rats. This approach enabled unbiased analysis of over 6300 proteins per group in DDA and over 8700 in DIA. Consistent across all analytical methods, chronic CLO administration induced robust downregulation of the serotonin 5‐HT2A receptor (5HTR2A) in both PFC and CX, whereas risperidone (RIS) exhibited no significant effect on 5‐HTR2A levels at clinically relevant doses. Despite sharing high affinity for this receptor, CLO and RIS elicited markedly distinct signalling profiles. In the PFC, CLO inhibited serotonergic, G‐protein (Gαq and Gβγ), calcium, and cytoskeletal signalling pathways, accompanied by strong downregulation of phospholipase C delta 4 (PLCδ4), an isoform implicated in suicidal behaviour. Concurrently, CLO upregulated calcium‐independent phospholipase A2γ (iPLA2γ) and guanylyl cyclase C (GUCY2C), suggesting potential modulation of docosahexaenoic acid (DHA) signalling and cGMP‐driven synaptic plasticity. In contrast, RIS predominantly activated Gαi, Gαz, and Gβγ signalling in the CX and enhanced mitochondrial function. RIS also upregulated GUCY2C. Both drugs differentially modulated protein networks associated with potential heteromeric complexes involving 5HTR2As, including interactions with 5‐HT1A, 5‐HT2C, dopamine D2, oxytocin and cannabinoid CB1 receptors, highlighting their impact on complex serotonergic modulation. Notably, despite CLO's suppression of Gαq signalling, compensatory upregulation of Gαi was not observed, indicating a net attenuation of 5HTR2A‐mediated output rather than a simple G‐protein coupling switch. These findings advance our understanding of serotonergic, metabolic and receptor‐level adaptations induced by atypical antipsychotics and suggest that CLO's superior efficacy may derive from its unique ability to downregulate 5HTR2A and remodel signalling networks beyond classical dopaminergic mechanisms. image

  • Open Access

    Medium-resolution cryo-EM structure of the Danio rerio tRNA ligase complex

    by Chamera S, Zajko W, Czarnocki-Cieciura M, Jaciuk M, Koziej Ł, Nowak J, Wycisk K, Sroka M, Chramiec-Głąbik A, Śmietański M, et al.

    EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.

  • Open Access

    Glycosaminoglycans act as activators of peptidylarginine deiminase 4

    by Grzegorz P. Bereta, Ewa Bielecka, Karolina Marzec, Łukasz Pijanowski, Artur Biela, Piotr Wilk, Marta Kamińska, Jakub Nowak, Elżbieta Wątor, Przemysław Grudnik, et al.

    Peptidylarginine deiminase 4 (PAD4) is a citrullinating enzyme that is gathering increasing attention due to its possible involvement in physiological processes as well as in the pathogenesis of diseases like rheumatoid arthritis or thrombosis. PAD4 is activated by calcium ions, but the details of this mechanism are elusive, because in the human body, Ca 2+ concentrations are too low for full activity. Given that glycosaminoglycans (GAGs) are also implicated in the development and progression of rheumatoid arthritis, we investigated the activation of PAD4 by GAGs using heparin as a model. We employed activity assays, chromatography techniques, molecular interaction measurements (MST and SPR), FACS, and immunocytochemistry to demonstrate the activation of PAD4 by GAGs. Our data show that PAD4 binds heparin with high affinity and forms high molecular weight complexes with heparin, consistent with heparin-bound tetramer formation. Heparin activates PAD4 by increasing the enzyme’s Ca 2+ affinity threefold. We also show that the effectiveness of activation with heparin depends on the length of GAG used and its negative charge. Direct measurement of heparin binding to PAD4 confirmed tight interaction with nanomolar affinity. Mutagenesis of regions likely responsible for heparin binding showed that dimerization of PAD4 is necessary for efficient activation, but the distinct binding site was not determined as interaction with heparin likely occurs over larger surface of PAD4. Furthermore, we show that other GAG family members, including heparan and chondroitin sulphates, are also able to activate PAD4. We also found that disturbed production of GAGs by CHO cells results in reduced PAD4 binding efficiency. Finally, heparin induces NETosis in hPMNs in concentration-dependent manner, as measured by the release of DNA and citrullination of histone H3. In summary, we identify the first natural coactivator of PAD4, which is present in all individuals, potentially explaining the regulation of PAD4 activity in physiological conditions, and providing new insight into the development of rheumatoid arthritis and other PAD4-related diseases.


  • Open Access

    Conserved structures and dynamics in 5′-proximal regions of Betacoronavirus RNA genomes

    by Tales Rocha de Moura, Elżbieta Purta, Agata Bernat, Eva M Martín-Cuevas, Małgorzata Kurkowska, Eugene F Baulin, Sunandan Mukherjee, Jakub Nowak, Artur P Biela, Michał Rawski, et al.

    Betacoronaviruses are a genus within the Coronaviridae family of RNA viruses. They are capable of infecting vertebrates and causing epidemics as well as global pandemics in humans. Mitigating the threat posed by Betacoronaviruses requires an understanding of their molecular diversity. The development of novel antivirals hinges on understanding the key regulatory elements within the viral RNA genomes, in particular the 5′-proximal region, which is pivotal for viral protein synthesis. Using a combination of cryo-electron microscopy, atomic force microscopy, chemical probing, and computational modeling, we determined the structures of 5′-proximal regions in RNA genomes of Betacoronaviruses from four subgenera: OC43-CoV, SARS-CoV-2, MERS-CoV, and Rousettus bat-CoV. We obtained cryo-electron microscopy maps and determined atomic-resolution models for the stem-loop-5 (SL5) region at the translation start site and found that despite low sequence similarity and variable length of the helical elements it exhibits a remarkable structural conservation. Atomic force microscopy imaging revealed a common domain organization and a dynamic arrangement of structural elements connected with flexible linkers across all four Betacoronavirus subgenera. Together, these results reveal common features of a critical regulatory region shared between different Betacoronavirus RNA genomes, which may allow targeting of these RNAs by broad-spectrum antiviral therapeutics.


  • Kartogenin-loaded liposomes coated with alkylated chondroitin sulfate for cartilage repair

    by Magdalena Wytrwal, Katarzyna Szmajnta, Miroslaw Kucharski, Jakub Nowak, Ewa Oclon, Mariusz Kepczynski


  • Open Access

    Destabilization of mutated human PUS3 protein causes intellectual disability

    by Ting‐Yu Lin, Robert Smigiel, Bozena Kuzniewska, Joanna J. Chmielewska, Joanna Kosińska, Mateusz Biela, Anna Biela, Anna Kościelniak, Dominika Dobosz, Izabela Laczmanska, et al.

    Pseudouridine (Ψ) is an RNA base modification ubiquitously found in many types of RNAs. In humans, the isomerization of uridine is catalyzed by different stand‐alone pseudouridine synthases (PUS). Genomic mutations in the human pseudouridine synthase 3 gene (PUS3) have been identified in patients with neurodevelopmental disorders. However, the underlying molecular mechanisms that cause the disease phenotypes remain elusive. Here, we utilize exome sequencing to identify genomic variants that lead to a homozygous amino acid substitution (p.[(Tyr71Cys)];[(Tyr71Cys)]) in human PUS3 of two affected individuals and a compound heterozygous substitution (p.[(Tyr71Cys)];[(Ile299Thr)]) in a third patient. We obtain wild‐type and mutated full‐length human recombinant PUS3 proteins and characterize the enzymatic activity in vitro. Unexpectedly, we find that the p.Tyr71Cys substitution neither affect tRNA binding nor pseudouridylation activity in vitro, but strongly impair the thermostability profile of PUS3, while the p.Ile299Thr mutation causes protein aggregation. Concomitantly, we observe that the PUS3 protein levels as well as the level of PUS3‐dependent Ψ levels are strongly reduced in fibroblasts derived from all three patients. In summary, our results directly illustrate the link between the identified PUS3 variants and reduced Ψ levels in the patient cells, providing a molecular explanation for the observed clinical phenotypes.